Use of recombinant human chorionic gonadotropin in ovulation induction

Slides:

Advertisements

Similar presentations

Lisa Marii Cookingham, M. D. , Rachel P. Goossen, B. A. , Amy E. T

Advertisements

Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.

Elevated serum progesterone level on the day of human chorionic gonadotropin administration does not adversely affect implantation rates after intracytoplasmic.

Are good patient and embryo characteristics protective against the negative effect of elevated progesterone level on the day of oocyte maturation? Micah.

Is the effect of premature elevated progesterone augmented by human chorionic gonadotropin versus gonadotropin-releasing hormone agonist trigger? Matthew.

Effects of follicle-stimulating hormone and human chorionic gonadotropin on gonadal steroidogenesis in two siblings with a follicle-stimulating hormone.

Evaluation of basal estradiol levels in assisted reproductive technology cycles2 John L Frattarelli, M.D., Paul A Bergh, M.D., Michael R Drews, M.D.,

Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.

Decreased inhibin B responses following recombinant human chorionic gonadotropin administration in normal women and women with polycystic ovary syndrome

Ovarian response to the human chorionic gonadotrophin stimulation test in normal ovulatory women: the impact of regressing corpus luteum Ilkka Y. Järvelä,

1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.

Hongxia Li, M. D. , Jiangang Chen, M. D. , James W Overstreet, M. D

Is chemiluminescent immunoassay an appropriate substitution for radioimmunoassay in monitoring estradiol levels? Avner Hershlag, M.D., Michael Zinger,

Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy Ewa Nowak-Markwitz,

Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.

Orhan Bukulmez, M. D. , Qin Li, M. S. , Bruce R. Carr, M. D

Modified natural cycle in in vitro fertilization

Serum human chorionic gonadotropin levels are correlated with body mass index rather than route of administration in women undergoing in vitro fertilization–embryo.

Human chorionic gonadotropin as a predictor of outcome in assisted reproductive technology pregnancies Gillian Homan, Susan Brown, R.N., John Moran,

Subcutaneous versus intramuscular administration of human chorionic gonadotropin during an in vitro fertilization cycle James R. Stelling, M.D., Emily.

Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D.

The role of steroid hormone supplementation in non–assisted reproductive technology treatments for unexplained infertility Alexander M. Quaas, M.D.,

Christine L Cook, M. D. , Yong Siow, Ph. D. , Susan Taylor, B. A

High serum luteinizing hormone and testosterone concentrations do not predict pregnancy outcome in women with recurrent miscarriage Luciano G Nardo,

Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.

How and when human chorionic gonadotropin curves in women with an ectopic pregnancy mimic other outcomes: differences by race and ethnicity Katherine.

Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response Frank.

Chao-Chin Hsu, M. D. , Ph. D. , Hsin-Chih Kuo, Ph. D

Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review Seema Menon, M.D., John.

Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity Helen Sullivan,

Lisa Marii Cookingham, M. D. , Rachel P. Goossen, B. A. , Amy E. T

Robert F. Casper, M.D. Fertility and Sterility

A prospective randomized clinical trial of differing starter doses of recombinant follicle- stimulating hormone (follitropin-β) for first time in vitro.

Success of intrauterine insemination in women aged 40–42 years

Conversion of high-response gonadotropin intrauterine insemination cycles to in vitro fertilization results in excellent ongoing pregnancy rates Amy.

Are serum human chorionic gonadotropin clearance curves of use in monitoring methotrexate treatment in cervical pregnancy? Petra J. Hajenius, M.D., Daphne.

A unique biological in-vivo model to evaluate follicular development during in-vitro maturation treatment S.E. Elizur, W.Y. Son, H. Clarke, D. Morris,

Clinical Assessment of Recombinant Human Follicle-Stimulating Hormone in Stimulating Ovarian Follicular Development Before In Vitro Fertilization fn1

Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.

Modulation of HOXA10 and other markers of endometrial receptivity by age and human chorionic gonadotropin in an endometrial explant model Robin H. Fogle,

Serum insulin-like factor 3 is highly correlated with intratesticular testosterone in normal men with acute, experimental gonadotropin deficiency stimulated.

Effect of letrozole at 2. 5 mg or 5

Granulosa–lutein cell growth differentiation factor-9 (GDF-9) messenger RNA and protein expression in in vitro fertilization (IVF) cycles: relation to.

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Rina Agrawal,

Concentrations of inhibins and activin in women undergoing stimulation with recombinant follicle-stimulating hormone for in vitro fertilization treatment

Orhan Bukulmez, M. D. , Bruce R. Carr, M. D. , Kathleen M. Doody, M. D

Endocrine gland–derived vascular endothelial growth factor concentrations in follicular fluid and serum may predict ovarian hyperstimulation syndrome.

David E. Reichman, M. D. , Stacey A. Missmer, Sc. D. , Katharine F

Luteal support with intravaginal progesterone increases clinical pregnancy rates in women with polycystic ovary syndrome using letrozole for ovulation.

Aviad Cohen, M. D. , Guy Bibi, M. D. , Benny Almog, M. D

Are gestational age and endometrial thickness alternatives for serum human chorionic gonadotropin as criteria for the diagnosis of ectopic pregnancy?

A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro.

Effectiveness of highly purified human menopausal gonadotropin vs

Regulation of assisted reproductive technologies in the United States

Decreased levels of interleukin-18 in peritoneal fluid but not in serum of patients with endometriosis Xinmei Zhang, M.D., Jun Lin, M.D., Yuli Qian,

Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome Derek A Haas, M.D., Bruce.

Absence of corpus luteum rescue by chorionic gonadotropin in women immunized with a contraceptive vaccine Rahul Pal, Ph.D., Om Singh, Ph.D. Fertility.

Kayoko Takata, M. D. , Nobuhiko Suganuma, M. D. , Hisae Wada, M. D

Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization David W. Schmidt, M.D.,,

Value of the serum estradiol level on the day of human chorionic gonadotropin injection and on the day after in predicting the outcome in natural in vitro.

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Luteal phase support Fertility and Sterility

Lower levels of inhibin A and pro-αC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human.

First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for.

Increased endometrial thickness on the day of human chorionic gonadotropin injection does not adversely affect pregnancy or implantation rates following.

Conversion from assisted reproductive technology to intrauterine insemination in low responders: Is it advantageous? John M. Norian, M.D., Eric D. Levens,

Serum human chorionic gonadotropin level after ovulation triggering is influenced by the patient’s body mass index and the number of larger follicles

Logarithmic curves depicting initial level and rise of serum beta human chorionic gonadotropin and live delivery outcomes with in vitro fertilization:

Effect of obesity on recombinant follicle-stimulating hormone absorption: subcutaneous versus intramuscular administration Michael P Steinkampf, M.D.,

Low-dose human chorionic gonadotropin therapy can improve sensitivity to exogenous follicle-stimulating hormone in patients with secondary amenorrhea

Presentation transcript:

Use of recombinant human chorionic gonadotropin in ovulation induction M.ichael Ludwig, MD, Kevin J Doody, MD, Kathleen M Doody, MD Fertility and Sterility Volume 79, Issue 5, Pages 1051-1059 (May 2003) DOI: 10.1016/S0015-0282(03)00173-0

FIGURE 1 Time from injection of hCG (6,000 IU IM) to follicle rupture in an IUI cycle. Evaluation of 37 cycles in 32 women. Data according to (8). Ludwig. Recombinant hCG. Fertil Steril 2003. Fertility and Sterility 2003 79, 1051-1059DOI: (10.1016/S0015-0282(03)00173-0)

FIGURE 2 Course of hCG serum concentration after administration of 5,000 IU r-hCG (250 μg) and 5,000 IU u-hCG. Reprinted with permission from (22). Ludwig. Recombinant hCG. Fertil Steril 2003. Fertility and Sterility 2003 79, 1051-1059DOI: (10.1016/S0015-0282(03)00173-0)